Skip to content
AiSeekAiSeek
Sign in
NewHealthPolicyScienceReported 2026-10-09 20:45

Milestone Pharmaceuticals Enrolls First European Patient in ReVeRA-301 Phase 3 Clinical Trial

Milestone Pharmaceuticals has enrolled the first European patient in the ReVeRA-301 Phase 3 clinical trial for etripamil nasal spray to treat atrial fibrillation with rapid ventricular rate (AFib-RVR).

Why it matters. This milestone advances the development of a potential new treatment for AFib-RVR, which affects millions of people globally.

01

Who it touches

  1. 1Milestone Pharmaceuticals
  2. capacity constraint →Fact
    2capital resourcesasset
  3. regulatory exposure →Fact
    3U.S. Food and Drug AdministrationGovernment
02

Evidence

  • GGDELT Global Knowledge GraphMedia2026-10-09 20:45
    View source
  • GGDELT Global Knowledge GraphMedia2026-10-09 20:45
    View source